Lumix Superpulsed lasers produce the highest pulse power and simultaneously emit the strongest average power of any therapeutic laser in the US today.
The 3 P’s of Performance: Power, Penetration, Pulse
- Adequate amounts of pulse and average powers are essential for successful patient results.
- Research shows high pulse rates initiate cellular regeneration.
- Published research found combining superpulsed and continuous wave (CW) wavelengths allows CW emission to be delivered more deeply. Combining these two emissions increases the efficacy and safety of laser therapy.
- Published research demonstrates the promotion of gene expression and cellular regeneration when pulse rates are above 30,000 Hz (30 kHz). This is critical to repairing tissue and relieving pain.
What do Wavelengths Effect?
Lumix superpulsed lasers effect deep tissue penetration. Equipped with multiple wavelengths, these lasers provide multidimensional therapeutic benefits. Additionally-
- The superpulsed lasers emission is more clinically efficient than continuous wave emission alone, according to recent research.
- Both CW and superpulsed emissions activate anti-inflammatory and normalizing mechanisms at the cellular level. This is true for any tissue, from muscle, tendon and bone to ligament, skin and nerve.
- Superpulsed wavelength emission penetrates deeply, yet is almost completely non-thermal.
Laser Biotech offers three lasers in the Lumix Series: Lumix 2, Lumix 3, and Lumix 4 — named according to the number of wavelengths in the design:
- Lumix 2 Series focus on superpulsed emission of 910 nm combined with CW wavelength of 650 nm. FDA cleared Class 3b and Class 4 in 2004.
- Lumix 3 Series are superpulsed (910 nm) and combine with CW wavelength options of 650 nm and an additional 810, 980 or 1064 nm to deliver multidimensional laser therapy. FDA cleared Class 4 in 2016.
- Lumix 4 Series are superpulsed (910 nm) and combine with 650 nm and an additional two 810, 980, or 1064 CW wavelengths. This allows practitioners to effectively treat a larger range of clinical applications. FDA cleared Class 4 in 2016.